Nuntius Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Early Stage VC
- Investors
-
5
Nuntius Therapeutics General Information
Description
Developer of genetic medicines designed to cure patients with life-threatening diseases. The company develops mRNA therapies and gene editing therapies by leveraging proprietary delivery technology, machine learning, and nucleic acid engineering, enabling healthcare professionals to treat incurable diseases and improve patient outcomes.
Contact Information
Website
www.nuntiustx.comCorporate Office
- Unit 23 The Cobalt Building, Lower Pemberton
- Kent
- Ashford TN25 4BF
- England, United Kingdom
Corporate Office
- Unit 23 The Cobalt Building, Lower Pemberton
- Kent
- Ashford TN25 4BF
- England, United Kingdom
Nuntius Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 01-Apr-2021 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 23-Mar-2021 | Completed | Generating Revenue |
Nuntius Therapeutics Patents
Nuntius Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202216550-D0 | Extrahepatic delivery | Inactive | 07-Nov-2022 | ||
| GB-202216131-D0 | Extrahepatic delivery | Inactive | 31-Oct-2022 | ||
| GB-202212998-D0 | Molecular fingerprinting | Inactive | 06-Sep-2022 | ||
| EP-4581633-A1 | Methods for characterisation of nanocarriers | Pending | 02-Sep-2022 | ||
| GB-202212806-D0 | Methods for characterisation of nanocarriers | Inactive | 02-Sep-2022 | G16C60/00 |
Nuntius Therapeutics Signals
Nuntius Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Asymmetry Ventures | Venture Capital | Minority | ||
| Backed | Venture Capital | Minority | ||
| FoundersX Ventures | Venture Capital | Minority | ||
| Uncommon Denominator | Venture Capital | Minority | ||
| Y Combinator | Accelerator/Incubator | Minority |
Nuntius Therapeutics FAQs
-
When was Nuntius Therapeutics founded?
Nuntius Therapeutics was founded in 2021.
-
Where is Nuntius Therapeutics headquartered?
Nuntius Therapeutics is headquartered in Ashford, United Kingdom.
-
What is the size of Nuntius Therapeutics?
Nuntius Therapeutics has 8 total employees.
-
What industry is Nuntius Therapeutics in?
Nuntius Therapeutics’s primary industry is Drug Discovery.
-
Is Nuntius Therapeutics a private or public company?
Nuntius Therapeutics is a Private company.
-
What is Nuntius Therapeutics’s current revenue?
The current revenue for Nuntius Therapeutics is .
-
How much funding has Nuntius Therapeutics raised over time?
Nuntius Therapeutics has raised $125K.
-
Who are Nuntius Therapeutics’s investors?
Asymmetry Ventures, Backed, FoundersX Ventures, Uncommon Denominator, and Y Combinator have invested in Nuntius Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process